<DOC>
	<DOCNO>NCT02860481</DOCNO>
	<brief_summary>FRACTal study first exploration detection FSHR blood biomarker diagnosis cancer . A first cohort explore several common ( e.g . breast , prostate ) rare ( e.g . uveal melanoma ) cancer , frequently treat Institut Curie . This first cohort include n=10 patient per histological type except breast cancer ( n=50 ) . 100 patient expect cohort . A second cohort explore promising histological type ( ) term incidence detection . 100 patient expect second cohort .</brief_summary>
	<brief_title>FSH-R : Diagnostic Application Localized Tumors Cancerology</brief_title>
	<detailed_description />
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Inclusion criterion 1 . Patient diagnose localized cancer correspond different type explore . The cancer already diagnose ( strong suspicion ) 2 . Age &gt; 18 3 . Written inform consent Exclusion criterion 1 . Previous treatment tumoral disease 2 . Personal history cancer diagnosis last 10 year 3 . Pregnant and/or breastfeed woman 4 . Person deprive liberty guardianship ( include curatorship ) 5. psychiatric illness/social situation would interfere protocol limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>